Acute Lymphoblastic Leukemia, Version 2.2015

Area of Science:

• Hematology
• Oncology
• Leukemia Research

Background:

• Acute lymphoblastic leukemia (ALL) treatment is evolving with improved risk stratification and novel therapeutic strategies.
• Subtyping ALL using immunophenotyping, cytogenetics, and molecular markers refines prognosis, identifying entities like Philadelphia-like ALL and early T-cell precursor ALL.
• Ikaros mutations are recognized as a significant prognostic indicator in ALL.

Purpose of the Study:

• To summarize recent advancements in acute lymphoblastic leukemia (ALL) treatment guidelines.
• To highlight the importance of risk stratification, novel therapies for relapsed/refractory ALL, and minimal residual disease (MRD) monitoring.
• To provide an overview of clinical presentation, diagnosis, and treatment modifications based on MRD.

Main Methods:

• Review of updated clinical guidelines for acute lymphoblastic leukemia (ALL).
• Focus on diagnostic criteria, prognostic markers (subtypes, mutations), and therapeutic advancements.
• Integration of minimal residual disease (MRD) monitoring into treatment strategies.

Main Results:

• Improved prognostication through identification of specific ALL subtypes and molecular markers.
• Expanded treatment options for relapsed/refractory ALL, including tyrosine kinase inhibitors and immunotherapy (blinatumomab, CAR T-cell therapy).
• Minimal residual disease (MRD) monitoring provides insights into patient outcomes and informs treatment adjustments.

Conclusions:

• Recent advancements in ALL treatment, including subtype identification and novel therapies, have improved survival rates.
• Minimal residual disease (MRD) monitoring is crucial for personalized treatment strategies and optimizing patient outcomes.
• Updated guidelines offer improved approaches to diagnosis and management of relapsed/refractory ALL.